Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GNRHR | P30968 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2283690 | 0.86 | CHRM1 (0.71) | CHRM1CNR2ALDH1A1HTTLMNA | |
| SCHEMBL7921098 | 0.85 | CHRM1 (0.48) | CHRM1P2RX3KMT2AALDH1A1LMNA | |
| SCHEMBL1931223 | 0.85 | CHRM1 (0.58) | CHRM1GNRHRP2RX3KMT2AALDH1A1 | |
| SCHEMBL7937581 | 0.85 | CHRM1 (0.58) | CHRM1GNRHRP2RX3KMT2AGAA | |
| SCHEMBL2288496 | 0.85 | CHRM1 (0.47) | CHRM1GNRHRP2RX3KMT2AALDH1A1 | |
| SCHEMBL14922852 | 0.84 | CHRM1 (0.50) | CHRM1GNRHRP2RX3KMT2AALDH1A1 | |
| SCHEMBL2490472 | 0.78 | CHRM1 (0.52) | CHRM1GNRHRKMT2ATSHRMEN1 | |
| SCHEMBL1347254 | 0.78 | SMN1; SMN2 (0.53) | CHRM1THRBGNRHRP2RX3LMNA | |
| SCHEMBL1550162 | 0.78 | CHRM1 (0.50) | CHRM1GNRHRP2RX3KMT2AALDH1A1 | |
| SCHEMBL1550419 | 0.78 | CHRM1 (0.50) | CHRM1GNRHRP2RX3KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-8436016-B2 | Fused heterocyclic M1 receptor positive allosteric modulators | Merck, Sharp & Dohme, Corp. | 2013-05-07 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | Merck, Sharp & Dohme, Corp. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201607-A1 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, OPRL1, OPRM1 | CHRM1 1/4885THRB 488/4885GNRHR 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.